Oncodrivers in Advanced or Metastatic NSCLC: Current and Future Standards of Care

Panelists discuss the evolving management of advanced and metastatic non–small cell lung cancer driven by key oncogenic alterations, emphasizing advancements in molecular diagnostics, targeted treatment development, resistance mechanisms, and personalized sequencing strategies that continue to redefine the modern standard of care.

EP. 1: ALK Alterations and Treatment Options for ALK+ NSCLC

November 5th 2025

Panelists discuss the role of ALK rearrangements in lung cancer and the development of successive generations of targeted inhibitors.

EP. 2: Long-Term Data in ALK+ NSCLC

November 5th 2025

Panelists discuss long-term data demonstrating the durability of response and intracranial protection achieved with modern ALK-targeted therapies.

EP. 3: Spotlight on ROS1-Targeted Therapies in Advanced NSCLC

November 5th 2025

Panelists discuss the molecular and clinical characteristics of ROS1-driven lung cancer and the role of precise molecular testing in guiding targeted therapy.

EP. 4: Treatment Options for ROS1+ Advanced NSCLC

November 5th 2025

Panelists discuss first-line treatment strategies for ROS1-positive lung cancer and the factors influencing therapy selection and sequencing.

EP. 5: Investigational Therapies and Ongoing Trials in ROS1+ NSCLC

November 12th 2025

Panelists discuss ongoing research and investigational strategies aimed at overcoming resistance in ROS1-driven lung cancer.

EP. 6: Use of ROS1-Targeting Agents in Clinical Practice

November 12th 2025

Panelists discuss translating clinical trial evidence on ROS1-targeted therapy into real-world patient management.

EP. 7: Using Long-Term Data to Guide ALK+ NSCLC Treatment

November 26th 2025

Panelists discuss how mature survival data inform treatment sequencing and maintenance strategies in ALK-positive lung cancer.

EP. 8: Real-World Data in ALK+ NSCLC

November 26th 2025

Panelists discuss how real-world data complement clinical trials in understanding outcomes for ALK-positive lung cancer.

EP. 9: Resistance Mechanisms and Molecular Testing in ALK Inhibitor–Treated NSCLC

December 5th 2025

Panelists discuss mechanisms of acquired resistance to ALK inhibition and how molecular testing guides sequencing strategies.

EP. 10: Emerging Strategies for ALK+ NSCLC

December 5th 2025

Panelists discuss novel research directions aimed at overcoming resistance and extending survival in ALK-positive lung cancer.